Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I assume they do..... they're not incompetents, but I too would think the sales growth would be greater. Very frustrating!!
SEE ORELLI ARTICLE .... MOTLEY FOOL
Exercise price $1.50. 5 year options. Believe they expire in 2021.
There will be a 3Q conference call early November & possible update on FDA & 5211 partnering.
I don't see where this release says anything about meeting with the FDA to discuss phase III needs??
My understanding was different. I believe VKTX last indicated it had a meeting scheduled with the FDA in September & suggested potential partners were awaiting the results of the FDA meeting.
Has anyone seen whether or not they've had the meeting with the FDA?
Other than long, is it worth listening? Anything worth hearing? Thanks!!
I think Madrigal just raised $300M @ $305 a share??
It's a coin flip...... particularly now that it completed it's funding for awhile. Obviously it's anticipated that good news is forthcoming but anything can happen & often does.
We need the partner & the FDA meeting re:5211
Hi
Thanks for attending & asking the questions. I live 2 hours North & will try to make it next year. Ligand holds its S/H meeting at 8:30 am also & gets a poor turnout. Don't think they want more.
I'm a little confused by your comment...... did they explain why they reneged on releasing the 24 week top line data after they said they would release it around the end of 1Q18? Did they give U any indication as to whether the 24 week data confirmed the 12 week data?
Thanks!!
It's my recollection that the CEO previously said that they would have the 24 week 5211 trial results by the end of 1Q18 & they would release the top line results, as they did with the 12 weeks results in November. Do they have the 24 week results & if so, why did they choose to renege on their prior statement? More importantly, are the 24 weeks results confirming of the 12 weeks results? Thanks!! Wish I could be there.
What's going to happen?
You'd think if it was that certain it would happen!! What does J & J gain by letting it drag on? If their intention is to buy GERN, why wouldn't J & J just do it when the market value is this low?
We should have the results from 2 vastly different phase 2 trials plus a possible partnership before the end of the year. It's the current lack of news that allows the shorts a free reign of terror.
What's there to talk about? Very disappointed there is no updated results on 5211. Must have completed the 24 week trial by now. Company said they would release the results but apparently decided to withhold the results for a conference?
What U say makes sense ...... thanks! However, if J & J makes meaningful acquisitions at these crazy prices, wouldn't it have to file with SEC which is in the public record & would be reported?
If this article is as right on as I'd like to believe, why wouldn't J & J just announce its continuation & let's get on with it!! This putting it off & the resulting manipulation shouldn't be allowed or tolerated!!
Why are U expecting a bounce before end of week?
Agree..... didn't CEO at last conference presentation indicate they intended to have a partner when they structured the P3 trial with the FDA? Also the Ligand business plan is to partner early??
Presentation is short. Nothing terribly new. Reiterated expect to have a partner for VK5211 before moving onto ph3. Seems like they extended time for reporting 24 week 5211 results from 1Q to 1H18.
Who's selling in this volume?
We're due for 24 week 5211 results in the next 4-6 weeks.Assuming consistent with 12 week results, what do you believe the impact will be? Might not have to wait for 2809 results??
Shareholder meeting is usually an annual event unless a special meeting is called.
At the last presentation the CEO said we should see 24 week P2 trial results on 5211 by end of Q1. Assuming the results build on the announced 12 week results, a good guess would be a $12 price should be reachable then. Anxious to hear what CEO says at 2/18 CC. Good luck to us!!
Investment Bankers valued at $10 a couple of years ago. Can't believe it languished so long at $1 or less. Based on progress, it's gotta be worth more today than a couple of years ago. A partner for 5211 should carry the proce a ways from current price.
At $5.03, are we getting any value for 2809? I realize we came back a ways from the 52 week low, but we're still only 1/2 way back to where the underwriters thought we were when doing the public offering 2 years ago??
Respecting 5211, at the Biotech Showcase the other day, I believe the CEO indicated they were observing the results over a 24 week period..... the original trial was 12 weeks..... & once compiled, they would release the top line data which he anticipated would be in 1Q18. They would then seek to go to the FDA & review the data with the FDA & discuss the structure of a registration trial. They indicated a hope to have a partner before commencing the registration trial.
CEO.... he is impressive!!
Presentation Monday!
Gotta be worth as much as it was at public offering!!
I believe when VKTX was taken public, the underwriter(s)were able to take it public at $10 per share. Nothing negative, that I can recall, has happened since it was valued at $10 per share....I believe its all been positive, albeit a little slower than anticipated.
Why would they hold KOL event prior to having the phase 2 data to release? What is gained by having pre-data?
This arrangement is consistent with the Ligand business model plus Ligand owns about 40% of VKTX.
Do U think they'd have this presentation prior to announcing the PII results? Guess anything is possible but i think it defies logic??
Agree..... not only the CEO but also the extremely successful major shareholder who discovered the compound & did the initial development & testing. Hope we're not setting ourselves up for a major disappointment!!
Assume U mean end of September?
Assume this morning's news release of a key opinion leader presentation on 10/9 indicates that's when VKTX is announcing the PII results of 5211? VKTX must be pretty confident??
Don't they keep putting back the time for the lipid data as well?
Thanks. I understand your point. I'm a long-time investor in Ligand & believe in the quality of their research & product development. I'm a holder of VKTXW because of a belief that VKTX will get at least 1 marketable product out of the 4 currently in development. If I'm wrong, the warrants will be a total loss, as will be the stock. If I'm right I will parse out of the warrants as you suggest.